Search

Your search keyword '"Brady, Samuel W."' showing total 232 results

Search Constraints

Start Over You searched for: Author "Brady, Samuel W." Remove constraint Author: "Brady, Samuel W."
232 results on '"Brady, Samuel W."'

Search Results

1. Uncovering novel mutational signatures by de novo extraction with SigProfilerExtractor

4. The genomic landscape of pediatric acute lymphoblastic leukemia

6. Chemotherapy and mismatch repair deficiency cooperate to fuel TP53 mutagenesis and ALL relapse

9. The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma

10. The acquisition of molecular drivers in pediatric therapy-related myeloid neoplasms

11. Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations

12. Table S6 from Clinical Significance of Novel Subtypes of Acute Lymphoblastic Leukemia in the Context of Minimal Residual Disease–Directed Therapy

13. Tables S1-S5 from Clinical Significance of Novel Subtypes of Acute Lymphoblastic Leukemia in the Context of Minimal Residual Disease–Directed Therapy

14. Data from Clinical Significance of Novel Subtypes of Acute Lymphoblastic Leukemia in the Context of Minimal Residual Disease–Directed Therapy

15. Supplementary Data-1 from Clinical Significance of Novel Subtypes of Acute Lymphoblastic Leukemia in the Context of Minimal Residual Disease–Directed Therapy

18. Data from Genomes for Kids: The Scope of Pathogenic Mutations in Pediatric Cancer Revealed by Comprehensive DNA and RNA Sequencing

19. Supplementary Tables S1-S5 from The Clonal Evolution of Metastatic Osteosarcoma as Shaped by Cisplatin Treatment

20. Supplementary Figure S2 from Genomes for Kids: The Scope of Pathogenic Mutations in Pediatric Cancer Revealed by Comprehensive DNA and RNA Sequencing

21. Data from St. Jude Cloud: A Pediatric Cancer Genomic Data-Sharing Ecosystem

23. Supplementary Figures S1-S11 from The Clonal Evolution of Metastatic Osteosarcoma as Shaped by Cisplatin Treatment

25. Data from The Clonal Evolution of Metastatic Osteosarcoma as Shaped by Cisplatin Treatment

26. Supplementary Tables from Genomes for Kids: The Scope of Pathogenic Mutations in Pediatric Cancer Revealed by Comprehensive DNA and RNA Sequencing

27. Supplementary Tables from St. Jude Cloud: A Pediatric Cancer Genomic Data-Sharing Ecosystem

28. Supplementary Data from St. Jude Cloud: A Pediatric Cancer Genomic Data-Sharing Ecosystem

29. Data from The Small GTPase ARF6 Activates PI3K in Melanoma to Induce a Prometastatic State

30. Figure S2 from The Small GTPase ARF6 Activates PI3K in Melanoma to Induce a Prometastatic State

31. Supplementary Figure S5 from Src Inhibition Blocks c-Myc Translation and Glucose Metabolism to Prevent the Development of Breast Cancer

32. Data from Src Inhibition Blocks c-Myc Translation and Glucose Metabolism to Prevent the Development of Breast Cancer

33. Supplementary Table and Figure Legends from Src Inhibition Blocks c-Myc Translation and Glucose Metabolism to Prevent the Development of Breast Cancer

34. Table S1 from The Small GTPase ARF6 Activates PI3K in Melanoma to Induce a Prometastatic State

35. Supplementary Methods and References from Src Inhibition Blocks c-Myc Translation and Glucose Metabolism to Prevent the Development of Breast Cancer

36. Supplementary Table S1 from Src Inhibition Blocks c-Myc Translation and Glucose Metabolism to Prevent the Development of Breast Cancer

37. Supplementary Figure 2 from Concomitant Targeting of Tumor Cells and Induction of T-cell Response Synergizes to Effectively Inhibit Trastuzumab-Resistant Breast Cancer

38. Supplementary Figure 7 from Concomitant Targeting of Tumor Cells and Induction of T-cell Response Synergizes to Effectively Inhibit Trastuzumab-Resistant Breast Cancer

39. Supplementary Figure 3 from Concomitant Targeting of Tumor Cells and Induction of T-cell Response Synergizes to Effectively Inhibit Trastuzumab-Resistant Breast Cancer

40. Supplementary Figure 4 from Concomitant Targeting of Tumor Cells and Induction of T-cell Response Synergizes to Effectively Inhibit Trastuzumab-Resistant Breast Cancer

41. Supplementary Figure 9 from Concomitant Targeting of Tumor Cells and Induction of T-cell Response Synergizes to Effectively Inhibit Trastuzumab-Resistant Breast Cancer

42. Supplementary Figure 1 from Concomitant Targeting of Tumor Cells and Induction of T-cell Response Synergizes to Effectively Inhibit Trastuzumab-Resistant Breast Cancer

43. Supplementary Figure 8 from Concomitant Targeting of Tumor Cells and Induction of T-cell Response Synergizes to Effectively Inhibit Trastuzumab-Resistant Breast Cancer

44. Supplementary Table 1 from Concomitant Targeting of Tumor Cells and Induction of T-cell Response Synergizes to Effectively Inhibit Trastuzumab-Resistant Breast Cancer

45. Supplementary Figure Legends 1-9 from Concomitant Targeting of Tumor Cells and Induction of T-cell Response Synergizes to Effectively Inhibit Trastuzumab-Resistant Breast Cancer

46. Supplementary Figure 5 from Concomitant Targeting of Tumor Cells and Induction of T-cell Response Synergizes to Effectively Inhibit Trastuzumab-Resistant Breast Cancer

47. Supplementary Figure 6 from Concomitant Targeting of Tumor Cells and Induction of T-cell Response Synergizes to Effectively Inhibit Trastuzumab-Resistant Breast Cancer

49. Additional file 1 of Convergent evolution and multi-wave clonal invasion in H3 K27-altered diffuse midline gliomas treated with a PDGFR inhibitor

50. Additional file 2 of Convergent evolution and multi-wave clonal invasion in H3 K27-altered diffuse midline gliomas treated with a PDGFR inhibitor

Catalog

Books, media, physical & digital resources